PhRMA Members Spent $48.5 Billion On R&D In 2012
This article was originally published in The Pink Sheet Daily
A report by the industry advocacy group notes that the 31 PhRMA member companies invested 20.7% of domestic sales revenue in R&D efforts last year. The aggregate total of $48.5 billion is down slightly from 2011 and a bit further from the 2010 record amount of $50.7 billion.
You may also be interested in...
In its first quarter 2021 sales earnings report, Roche highlighted the strength of its diagnostics business as biosimilars cannibalize its pharmaceutical revenues. CEO Thomas Schinecker said the growth should continue.
US Drug Pricing Bill’s Prospects Will Be Shaped By Whether Public Worries More About Access Than Cost
HR 3 has been re-introduced, and some provisions may be attached to the White House’s infrastructure bill, but the government price negotiation system envisioned by the bill may fail – if industry can convince Congress to focus on access to medicines, not their cost.
High court’s decision that FTC lacks authority to seek monetary recovery in litigation is boon for drug makers who have been subject to hefty payouts in reverse settlement and other cases brought by the commission.